VCNX.OTC.PinkVaccinex, INC

Form 4: Albert Friedberg Reports Acquisition of VaccinEx Shares

Sentiment:

SEC Form 4 Filing


Albert Friedberg, a director and 10% owner of VaccinEx, Inc., reports acquiring 100 shares of common stock at $4.51 per share on August 9, 2024, and discloses beneficial ownership through related entities.

Summary

  • Albert Friedberg, a director and 10% owner of VaccinEx, Inc. filed a Form 4.
  • The report details a transaction on August 9, 2024, where 100 shares of common stock were acquired at a price of $4.51 per share.
  • Following the transaction, Mr. Friedberg directly owns 2,094 shares.
  • Mr. Friedberg also indirectly owns shares through Pan Atlantic Holdings Ltd. (180 shares), Friedberg Global-Macro Hedge Fund Ltd. (16,724 shares), and FCMI Parent Co. (780,624 shares).
  • FCMI Parent Co. also holds warrants to purchase VaccinEx common stock at various exercise prices and expiration dates.
  • Mr. Friedberg disclaims beneficial ownership of shares held by Pan Atlantic Holdings Ltd., Friedberg Global-Macro Hedge Fund Ltd., and FCMI Parent Co. except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document is a standard regulatory filing reporting a transaction. The purchase of shares by a director is mildly positive, but the overall impact is likely minimal.

Positives

  • The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and large shareholders, providing transparency into their trading activities. This filing indicates the trading activity of a director and significant shareholder of VaccinEx.

Comparison to Industry Standards

  • Form 4 filings are standard practice for publicly traded companies and their insiders.
  • The information provided is consistent with regulatory requirements for disclosing changes in beneficial ownership.

Stakeholder Impact

  • The transaction may have a minor positive impact on shareholder sentiment.

Key Dates

DateDescription
10/03/2023Date of warrant expiration for 214,285 shares at $14 held by FCMI Parent Co.
02/08/2024Date of warrant expiration for 118,226 shares at $14 held by FCMI Parent Co.
03/28/2024Date of warrant expiration for 102,960 shares at $7.64 held by FCMI Parent Co.
08/09/2024Date of transaction: Acquisition of 100 shares of common stock at $4.51 per share.
08/13/2024Date of filing of the Form 4.
10/03/2028Expiration date of warrant to buy 214,285 shares at $14.
02/08/2029Expiration date of warrant to buy 118,226 shares at $14.
03/28/2029Expiration date of warrant to buy 102,960 shares at $7.64.

Keywords

VaccinEx, Friedberg, VCNX, Beneficial Ownership, Form 4, Share Acquisition, Warrants, Director

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.